Priya Rastogi, MD, on Breast Cancer: Predicting the Benefit of Extended Letrozole Therapy

June 22, 2021 By The ASCO Post Staff

Priya Rastogi, MD, of the University of Pittsburgh, discusses results from the NRG Oncology/NSABP B-42 trial, which evaluated the utility of the 70-gene MammaPrint assay in predicting the benefit of extended letrozole therapy in patients who had completed 5 years of adjuvant endocrine therapy (Abstract 502).

Related Content